• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
American Outdoor Brands, Inc. - Common Stock
Canaf Invts Inc
Caribou Biosciences, Inc. - Common Stock
Metallic Minerals Corp
MicroSectors -3x Short Consumer Staples (XLP) ETNs
Mynaric AG - American Depository Shares
Protext Mobility Inc
Sassy Gold Corp
Seiko Epson Corp ADR
Splunk Inc. - Common Stock
Edit Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Metagenomi Therapeutics, Inc. - Common Stock (NQ:MGX)

0.8056 -0.0106 (-1.30%)
Delayed Quote Updated: 4:00 PM EDT, Oct 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 76,731
Open 0.8001
Bid (Size) 0.7920 (100)
Ask (Size) 0.9500 (900)
Prev. Close 0.8162
Today's Range 0.7900 - 0.8236
52wk Range 0.7690 - 2.940
Shares Outstanding N/A
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Metagenomi Therapeutics, Inc. to Participate in the Chardan 10th Annual Healthcare Conference
October 13, 2026
From Metagenomi Therapeutics, Inc.
Via GlobeNewswire
News headline image
Metagenomi Therapeutics, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference
September 01, 2026
From Metagenomi Therapeutics, Inc.
Via GlobeNewswire

Performance

52-Week Range 72.6% below 52-week high
0.8056
0.7752W Low 2.9452W High
1 Week 6.3% below 1-week high
0.791W Low 0.861W High

Metagenomi Therapeutics, Inc. - Common Stock (MGX) traded between $0.77 and $2.94 over the past 52 weeks and last traded at $0.81, 72.6% below its 52-week high. Over the past week it ranged between $0.79 and $0.86.

Past 12 Months
-0.8%
-29.9%
-33.4%
-45.6%
-51.8%
-72.1%
1W -$0.01
1M -$0.34
3M -$0.40
6M -$0.67
YTD -$0.86
1Y -$2.08

MGX was -72.1% over the past year, -45.6% over six months, -51.8% year to date, -0.8% in the last week.

12 Months vs Market
MGX
-72.1%
DIA
+10.4%
SPY
+12.2%
QQQ
+14.1%
IWM
+10.6%

Over the past 12 months MGX returned -72.1% versus DIA (Dow) +10.4%, SPY (S&P 500) +12.2%, QQQ (Nasdaq 100) +14.1% and IWM (Russell 2000) +10.6%.

Volume & Liquidity 0.51× 3-mo avg
Today 76,731 3-mo avg 149.0K
1W
93.4K
1M
161.5K
3M
149.0K
6M
163.6K
YTD
194.2K
1Y
235.4K

MGX most recently traded 76,731 shares against a 3-month average daily volume of 149.0K.

More News

Read More
News headline image
Metagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results
August 10, 2026
From Metagenomi Therapeutics, Inc.
Via GlobeNewswire
News headline image
Prolynx Names Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer as It Advances Multi-Program Obesity and Metabolic Disease Portfolio
July 15, 2026
From ProLynx Inc.
Via GlobeNewswire
News headline image
Metagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare Conference
May 28, 2026
From Metagenomi Therapeutics, Inc.
Via GlobeNewswire
News headline image
Metagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial Results
May 11, 2026
From Metagenomi Therapeutics, Inc.
Via GlobeNewswire
News headline image
Metagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing Efficiency
April 16, 2026
From Metagenomi Therapeutics, Inc.
Via GlobeNewswire
News headline image
Metagenomi Therapeutics Reports Business Updates and Full Year 2025 Financial Results
March 05, 2026
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Metagenomi Therapeutics, Inc. to Present at the 46th Annual TD Cowen Healthcare Conference
February 23, 2026
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Metagenomi Announces Corporate Name Change to Metagenomi Therapeutics, Inc. and Highlights Recent Business Milestones and 2026 Corporate Outlook
January 12, 2026
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference
December 01, 2025
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Metagenomi to Present at Jefferies Global Healthcare Conference in London
November 17, 2025
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Metagenomi Prioritizes Hemophilia A Program, Lays Off 25% Workforce ↗
November 12, 2025
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
November 12, 2025
Via Benzinga
News headline image
These stocks are moving in today's after hours session ↗
November 11, 2025
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
November 11, 2025
Via Benzinga
News headline image
Metagenomi Reports Third Quarter 2025 Financial Results and Announces Strategic Pipeline Prioritization and Leadership Updates
November 11, 2025
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Metagenomi Presents New Preclinical Data from MGX-001 Hemophilia A Program Supporting Advancement into Clinical Development
November 11, 2025
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Metagenomi Inc (NASDAQ:MGX) Q2 2025 Earnings: Revenue Surpasses Estimates, Loss Narrower Than Expected ↗
August 12, 2025
Via Chartmill
News headline image
Metagenomi Reports Business Updates and Second Quarter 2025 Financial Results
August 12, 2025
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Metagenomi Appoints Laurence Reid, PhD to its Board of Directors
August 11, 2025
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Which stocks are gapping on Wednesday? ↗
July 09, 2025
Via Chartmill
News headline image
Sam Altman Says He 'Didn't Think' Elon Musk Would Abuse Government Power, Tesla CEO Hits Back With 'Scam Altman' Jibe ↗
June 20, 2025
Via Benzinga
News headline image
Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst ↗
June 18, 2025
Via Benzinga
News headline image
Demystifying Metagenomi: Insights From 4 Analyst Reviews ↗
May 15, 2025
Via Benzinga

Frequently Asked Questions

Is Metagenomi Therapeutics, Inc. - Common Stock publicly traded?
Yes, Metagenomi Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Metagenomi Therapeutics, Inc. - Common Stock trade on?
Metagenomi Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Metagenomi Therapeutics, Inc. - Common Stock?
The ticker symbol for Metagenomi Therapeutics, Inc. - Common Stock is MGX on the Nasdaq Stock Market
What is the current price of Metagenomi Therapeutics, Inc. - Common Stock?
The current price of Metagenomi Therapeutics, Inc. - Common Stock is 0.8056
When was Metagenomi Therapeutics, Inc. - Common Stock last traded?
The last trade of Metagenomi Therapeutics, Inc. - Common Stock was at 10/23/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap